Table 2 Distribution of patients and control groups according to anti-Toxoplasma IgG, IgM, and ANA prevalence
From: Seroprevalence of Toxoplasma gondii among a group of Egyptian patients with type I diabetes mellitus
Groups | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Cases | Control | χ 2 | p value | OR | CI | ||||
No. | % | No. | % | Lower | Upper | ||||
Anti-Toxo IgG | |||||||||
Positive | 27 | 45.0 | 14 | 23.3 | 6.26 | 0.01* | 2.69 | 1.23 | 5.89 |
Negative | 33 | 55.0 | 46 | 76.7 | |||||
Anti-Toxo IgM | |||||||||
Positive | 3 | 5.0 | 0 | 0.0 | 3.077 | 0.24 | |||
Negative | 57 | 95.0 | 60 | 100.0 | |||||
ANA | |||||||||
Positive | 1 | 1.7 | 1 | 1.7 | 0.0 | 0.75 | 1 | 0.06 | 16.37 |
Negative | 59 | 98.3 | 59 | 98.3 | |||||